Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593350 | 0.89 | LMNA (0.36) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL29819607 | 0.88 | HSD17B10 (0.39) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL28625969 | 0.88 | HSD17B10 (0.39) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL18593349 | 0.83 | LMNA (0.38) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL18593347 | 0.82 | ELANE (0.37) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL18593346 | 0.80 | MTNR1A (0.42) | LMNATP53MAPTTDP1RXRA | |
| SCHEMBL27996361 | 0.79 | LMNA (0.38) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL18593348 | 0.77 | LMNA (0.38) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL29460442 | 0.77 | LMNA (0.38) | LMNATP53MAPTTDP1HSP90AA1 | |
| SCHEMBL18593345 | 0.76 | MAPT (0.45) | LMNATP53MAPTRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856208-B2 | Method for producing an arene with an aromatic C—N bond ortho to an aromatic C—O bond | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-01-02 | — | — | US | disclosed |
| US-20170066711-A1 | METHOD FOR PRODUCING AN ARENE WITH AN AROMATIC C-N BOND ORTHO TO AN AROMATIC C-O BOND | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066711-A1 | METHOD FOR PRODUCING AN ARENE WITH AN AROMATIC C-N BOND ORTHO TO AN AROMATIC C-O BOND | AOX1, NOX4, NOXO1 | LMNA 1484/4885TP53 1454/4885MAPT 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.